Antifungal susceptibilities of Cryptococcus neoformans

被引：45

作者：

Archibald, LK

Tuohy, MJ

Wilson, DA

Nwanyanwu, O

Kazembe, PN

Tansuphasawadikul, S

Eampokalap, B

Chaovavanich, A

Reller, LB

Jarvis, WR

Hall, GS

Procop, GW

机构：

[1] Ctr Dis Control & Prevent, Atlanta, GA USA

[2] Cleveland Clin Fdn, Cleveland, OH 44195 USA

[3] Lilongwe Cent Hosp, Lilongwe, Malawi

[4] Bamrasnaradura Hosp, Nonthaburi, Thailand

[5] Duke Univ, Durham, NC 27706 USA

来源：

EMERGING INFECTIOUS DISEASES | 2004年 / 10卷 / 01期

关键词：

D O I：

10.3201/eid1001.020779

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Susceptibility profiles of medically important fungi in less-developed countries remain uncharacterized. We measured the MICs of amphotericin B, 5-flucytosine, fluconazole, itraconazole, and ketoconazole for Cryptococcus neoformans clinical isolates from Thailand, Malawi, and the United States and found no evidence of resistance or MIC profile differences among the countries.

引用

收藏

页码：143 / 145

页数：3

相关论文

共 15 条

[1] Fever and human immunodeficiency virus infection as sentinels for emerging mycobacterial and fungal bloodstream infections in hospitalized patients ≥15 years old, Bangkok [J].

Archibald, LK ;

McDonald, LC ;

Rheanpumikankit, S ;

Tansuphaswadikul, S ;

Chaovanich, A ;

Eampokalap, B ;

Banerjee, SN ;

Reller, LB ;

Jarvis, WR .

JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (01) :87-92

[2] A hospital-based prevalence survey of bloodstream infections in febrile patients in Malawi: Implications for diagnosis and therapy [J].

Archibald, LK ;

McDonald, LC ;

Nwanyanwu, O ;

Kazembe, P ;

Dobbie, H ;

Tokars, J ;

Reller, LB ;

Jarvis, WR .

JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (04) :1414-1420

[3] Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States:: 1992 to 1994 and 1996 to 1998 [J].

Brandt, ME ;

Pfaller, MA ;

Hajjeh, RA ;

Hamill, RJ ;

Pappas, PG ;

Reingold, AL ;

Rimland, D ;

Warnock, DW .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) :3065-3069

[4] In-vitro susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole [J].

Davey, KG ;

Johnson, EM ;

Holmes, AD ;

Szekely, A ;

Warnock, DW .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (02) :217-220

[5] Multicenter comparison of the Sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory Standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms [J].

Espinel-Ingroff, A ;

Pfaller, M ;

Messer, SA ;

Knapp, CC ;

Killian, S ;

Norris, HA ;

Ghannoum, MA .

JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (03) :591-595

[6] In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs [J].

Franzot, SP ;

Hamdan, JS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :822-824

[7] Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe [J].

Heyderman, RS ;

Gangaidzo, IT ;

Hakim, JG ;

Mielke, J ;

Taziwa, A ;

Musvaire, P ;

Robertson, VJ ;

Mason, PR .

CLINICAL INFECTIOUS DISEASES, 1998, 26 (02) :284-289

[8] Variation in electrophoretic karyotype and antifungal susceptibility of clinical isolates of Cryptococcus neoformans at a university-affiliated teaching hospital from 1987 to 1994 [J].

Klepser, ME ;

Pfaller, MA .

JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (12) :3653-3656

[9] CRYPTOCOCCOSIS IN THE ERA OF AIDS - 100 YEARS AFTER THE DISCOVERY OF CRYPTOCOCCUS-NEOFORMANS [J].

MITCHELL, TG ;

PERFECT, JR .

CLINICAL MICROBIOLOGY REVIEWS, 1995, 8 (04) :515-&

[10]

National Committee for Clinical Laboratory Standards, 2002, REF METH BROTH DIL A